RxDoctor Payments Data

Nima Adimi, MD

Interventional Pain Medicine · Chaska, MNNPI 1801186614

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $70,643 of the $114,021 with a category attached, or 62.0%. 12 manufacturers reported payments, led by Nevro Corp. at 57.5% of the total. Among interventional pain medicine clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$114,021in general payments, 2019–2025

Across 255 payments — averaging $447.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$66K
  • Globus Medical$46K
  • Abbott$1K
  • Medtronic$515
  • Boston Scientific$272
  • Vertos Medical, Inc.$183
  • plus $343 from 6 others

What the payments were for

  • Consulting fees$13,41012%
  • Speaking & faculty fees$70,64362%
  • Travel & lodging$22,30420%
  • Food & beverage$7,6657%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,021 in reported general payments places this provider in the 95th percentile of 26 interventional pain medicine providers in Minnesota.

See all interventional pain medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$169,881
Medicare patients
333
Services billed
4,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pregabalin513$6,358
Celecoxib171$2,359
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen186$967
Gabapentin61$698
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen126$694
Tizanidine Hcl73$659
Cephalexin75$368
Oxycodone Hcl28$219
Clindamycin Hcl21$172
Duloxetine Hcl20$157
Methylprednisolone22$139
Meloxicam24$124
Cyclobenzaprine Hcl23$120
Tramadol Hcl39$45

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Chaska

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →